Foley & Lardner LLP partners Louis Lehot and Eric Chow authored the GEN article, “Strengthening the Flow of the Biotech Sector’s M&A Pipeline,” exploring the outlook of biotechnology companies seeking mergers and acquisitions to sustain revenue streams and open new markets as the expiration dates for the patents behind many major medications quickly approach.
Lehot and Chow assess the ongoing stream of scientific breakthroughs and technological innovations in the sector, changing market forces, the constant vigilance of venture capital investors, and the high costs often associated with biopharmaceutical acquisitions.
“Although the road ahead may be unpredictable, the fundamental dynamics of the life sciences sector are poised to fuel a renaissance in mergers and acquisitions,” the authors conclude.